Tardive dyskinesia causes involuntary movements in some people taking antipsychotic medications. Here’s what you need to know about this movement disorder. Antipsychotic medications are a mainstay of ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

Tardive dyskinesia, or TD, is a drug-induced movement disorder that can occur in individuals taking certain medications that block dopamine receptors in the brain. Most commonly, cases of TD are ...

Tardive Dyskinesia TD as a neurological disorder resulting in involuntary repetitive movement disorder as a disease of brain Neurology due to dopamine problems. What have studies said the role vitamin ...

TOPEKA, Kan. (WIBW) - More people are becoming familiar with tardive dyskinesia, due to a series of commercials for a certain medication. NAMI Kansas wants people who are living with the condition to ...

TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) ...

—According to new research, oral vertical dyskinesia (OVD), also known by the older term “rabbit syndrome,” may be part of a spectrum of symptoms of drug-induced parkinsonism and tardive dyskinesia, ...

—These investigators examined more than 2 decades’ worth of de-identified electronic health records to learn more about why tardive dyskinesia is likely to be underreported and misdiagnosed in routine ...

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of ...

After 5 weeks of taking 300 mg of lithium daily, a 76-year-old woman with lurasidone-induced tardive dyskinesia from treatment for Bipolar II Disorder experienced reduced impact, intensity, and ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...